The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Cisplatin plus high dose infusional 5-fluorouracil and leucovorin for breast cancer (BC) patients (pts) with hyperbilirubinemia secondary to liver metastases (mets).
 
Brett Huang
Honoraria - AstraZeneca; Daiichi Sankyo; Gilead Sciences; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche
Consulting or Advisory Role - Gilead Sciences
 
I-Chun Chen
No Relationships to Disclose
 
Tom Chen
Honoraria - AstraZeneca; Daiichi Sankyo; Eisai; Gilead Sciences; Lilly; Novartis; Roche; TTY Biopharm
Consulting or Advisory Role - AstraZeneca; Daiichi Sankyo; Eisai; Roche
Travel, Accommodations, Expenses - Eisai
 
Wei-li Ma
No Relationships to Disclose
 
Dwan-Ying Chang
No Relationships to Disclose
 
Ming-HAN Yang
No Relationships to Disclose
 
Zola Li
No Relationships to Disclose
 
Ching-Hung Lin
No Relationships to Disclose
 
Yen-Shen Lu
Honoraria - AstraZeneca; Daiichi Sankyo/UCB Japan; Eisai; EuroPharma; Lilly; Merck Sharp & Dohme; Novartis; Pfizer; Roche
Consulting or Advisory Role - Lilly; Novartis; Pfizer; Roche
Research Funding - AstraZeneca (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst)
Travel, Accommodations, Expenses - Novartis